Booth: Country/Region: China Mainland
Founded by a group of veterans from the US biopharmaceutical industry in 2004, Sundia MediTech Company Ltd. is now a leading Shanghai-based CRO company providing drug discovery and development services worldwide. In 2007, Sundia successfully merged with United PharmaTech and formed an alliance with HD Biosciences. With our technical expertise and excellent research facilities, we offer broad and integrated chemical synthesis (custom synthesis, library design and synthesis), medicinal chemistry (hit generation, lead optimization, and preclinical development), biological (early hit screening, assay development, in vitro and in vivo pharmacology, in vitro and in vivo DMPK), new technology platforms (molecular diagnostics and PBSDD and nanotechnology), and pharmaceutical development (process research and development, API manufacture, pre-formulation and formulation, analytical and QA/QC, CMC and regulatory submission) services.
Since its founding in 2004, the company's CRO service business has been growing at an amazing rate. It was consecutively named as one of the top 50 most valuable companies for investment in China in 2007 and 2008. In 2008, with its 928% revenue growth, Sundia ranked #52 in the Deloitte Technology Fast 500 Asia Pacific list and #16 in the Fast 50 China list. Our expansion through partnerships has been driven by growing demand from our clients. In the past 5 years, Sundia has successfully established collaborations with over 100 client companies in North America, Europe, and Japan.
For Sundia, our professional leadership is an important asset. Our management team is made up of scientists with advanced degrees or training and who have extensive working/management experience in North America. Our team has rich experience in organic synthesis, medicinal chemistry, process chemistry, biology, business management, and law. Our research team comprises over 600 employees (HQ), among which 70% have a Ph.D. or a MS; About 8% are overseas returnees.